Save over 80% on brand name Jakafi (Jakavi or Jukavi in Europe).
All English packaging except the 10mg strength.
According to the European Medicines Agency, brand name Jakavi originating from Europe is manufactured at the following site(s):Novartis Farmacéutica S.A.
Gran Via de les Corts Catalanes, 764
08013 Barcelona
SpainNovartis Pharma GmbH
Roonstrasse 25
90429 Nuremberg
Germany
Jakafi (Jakavi in UK) is used in the treatment of adults with an enlarged spleen or symptoms of myelofibrosis, Jakafi is also used in place of hydroxyurea where the patient is resistant or intolerant. Jakafi is prescribed by physicians with special treatment experience.
Information about Jakafi (Ruxolitinib)
Jakafi is a medication primarily used to treat certain blood disorders and conditions affecting the immune system. It works as a selective Janus kinase (JAK) inhibitor, targeting specific pathways involved in the inflammatory response and hematopoiesis.
Product Highlights
Inhibits JAK1 and JAK2, affecting signaling pathways for various cytokines and growth factors
A type of bone marrow cancer that disrupts the body's normal production of blood cells.
A blood disorder characterized by the overproduction of red blood cells.
A condition that can occur after a stem cell transplant, where the donor's immune cells attack the recipient's body.
Key Ingredient
Ruxolitinib
Key Benefits
Reduces symptoms such as spleen enlargement and blood counts in myelofibrosis and polycythemia vera.
Helps manage chronic inflammatory conditions like GVHD.
Offers an alternative treatment option for patients who may not respond to or cannot tolerate other therapies.
Direction of Use
Often starts at a lower dose, which may be adjusted based on the patient’s response and side effects.
Regular blood tests are recommended to monitor blood cell counts and liver function.
Proposed Jakafi Starting Doses
Platelet Count
Starting Dose
Greater than 200 X 109 /L
20 mg orally twice daily
100 X 109 /L to 200 X 109 /L
15 mg orally twice daily
Safety Concerns
Common side effects include infections, anemia, thrombocytopenia, and elevated liver enzymes.
Increased risk of serious infections due to immune suppression.
Avoid Jakafi (Ruxolitinib) If
You have a known hypersensitivity to ruxolitinib or any of its components.
You are currently taking strong CYP3A4 inhibitors or inducers, which can affect ruxolitinib metabolism.
You have active infections that require treatment or significant liver impairment.
